肝复乐对原发性肝癌肝动脉栓塞化疗增效减毒作用的临床观察.docVIP

精品论文 参考文献 肝复乐对原发性肝癌肝动脉栓塞化疗增效减毒作用的临床观察 张文华1 梁春辉2 贾文玲3 唐海涛4 梁 莹5 　　甘肃省武威肿瘤医院 甘肃武威 733000 　　摘要：目的 研究口服肝复乐对对原发性肝癌肝动脉栓塞化疗（TACE）的增效减毒作用治疗效果。方法　回顾性分析116例确诊的原发性肝癌患者，A组37例（125I粒子植入联合TACE及肝复乐治疗组），B组36例（TACE联合肝复乐治疗组），C组43例（单纯TACE治疗组），3组均于治疗后第3、6、12个月行CT扫描进行疗效评价，分别比较3组治疗后6个月、12个月的生存状态。3组有效率及生存状态比较均采用卡方检验，以P lt; 0.05为差异有统计学意义。结果 治疗3、6、12个月后，A组的有效率分别为78.4%、83.8%、24.3%，显著高于B组的44.4%、38.89%、8.3%和C组的39.5%、18.6%、4.6%，差异有统计学意义（p lt; 0.05）；治疗6和12个月后，A组生存率分别为89.2% 和32.4 %，明显高于B组的69.4%、16.7 %和C组的46.5%、9.3%，差异有统计学意义（p lt; 0.05）。治疗6个月后，B组的有效率和生存率分别为36.1%、16.7 %，明显高于C组的18.6%、46.5%，差异有统计学意义（p lt; 0.05）。结论 I125粒子植入联合TACE及肝复乐是治疗肝癌的有效方法，具有良好的应用前景。 　　关键词：125I粒子组织间植入；肝动脉栓塞化疗；肝复乐；原发性肝癌 　　【Abstract】Objective To investigate the treatment effect of 125I particles implantation combined TACE and Ganfule treat primary liver cancer.Methods Retrospective analysis of 116 cases of patients which was diagnosed with primary liver cancer，A group had 37 cases（125I particles implantation combined TACE and Ganfule treatment group），B group had 36 cases（TACE and Ganfule treatment group），C group had 36 cases（only TACE treatment group），Three groups were CT scan and curative effect evaluation after 3，6，12 months treatment，three groups were compared living condition after treatment for 6 months and 12 months.The efficient and living condition of three groups of comparison adopt chi-square test，P lt; 0.05 was statistically significant.Results After 3，6，12 months treatment，the efficient of group A respectively was 78.4%，83.8% and 24.3%，significantly higher than group B which was 44.4%，38.89%，44.4%，and higher than group C which was 39.5%，18.6% and 4.6%，The difference was statistically significant（p lt; 0.05）.After 6 and 12 months treatment，the survival rates of group A respectively was 89.2% and 32.4 %significantly higher than group B which was 69.4%，16.7 %，and higher than group C which was 18.6%，46.5%，The difference was statistically significant（p lt; 0.05）.Conclusion 125I particles implantation combined TACE a